JP2024520654A - 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその医療用使用 - Google Patents

3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその医療用使用 Download PDF

Info

Publication number
JP2024520654A
JP2024520654A JP2023574412A JP2023574412A JP2024520654A JP 2024520654 A JP2024520654 A JP 2024520654A JP 2023574412 A JP2023574412 A JP 2023574412A JP 2023574412 A JP2023574412 A JP 2023574412A JP 2024520654 A JP2024520654 A JP 2024520654A
Authority
JP
Japan
Prior art keywords
pharma
cycloalkyl
solvate
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520654A5 (cg-RX-API-DMAC7.html
Inventor
ボナッツィ,シモーネ
サーニジェンコ,アルチョム
ストロカ コブ,ジェニファー
デューハースト,ジャネッタ
ライアン ケリガン,ジョン
ソン,ムージュ
マリエ-フランス トムセン,ノエル
ワイエフ ティン,パメラ
オブライエン,ゲイリー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024520654A publication Critical patent/JP2024520654A/ja
Publication of JP2024520654A5 publication Critical patent/JP2024520654A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023574412A 2021-06-03 2022-06-01 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその医療用使用 Pending JP2024520654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196422P 2021-06-03 2021-06-03
US63/196,422 2021-06-03
PCT/IB2022/055131 WO2022254362A1 (en) 2021-06-03 2022-06-01 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof

Publications (2)

Publication Number Publication Date
JP2024520654A true JP2024520654A (ja) 2024-05-24
JP2024520654A5 JP2024520654A5 (cg-RX-API-DMAC7.html) 2025-05-30

Family

ID=82115547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574412A Pending JP2024520654A (ja) 2021-06-03 2022-06-01 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその医療用使用

Country Status (22)

Country Link
US (2) US12103919B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347580A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520654A (cg-RX-API-DMAC7.html)
KR (1) KR20240013812A (cg-RX-API-DMAC7.html)
CN (1) CN117062811A (cg-RX-API-DMAC7.html)
AR (1) AR126052A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022284366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215410A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000013A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230614A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000261A (cg-RX-API-DMAC7.html)
EC (1) ECSP24000004A (cg-RX-API-DMAC7.html)
IL (1) IL308094A (cg-RX-API-DMAC7.html)
JO (1) JOP20230308A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014327A (cg-RX-API-DMAC7.html)
PE (1) PE20240657A1 (cg-RX-API-DMAC7.html)
PY (1) PY2243958A (cg-RX-API-DMAC7.html)
TW (1) TW202306570A (cg-RX-API-DMAC7.html)
UY (1) UY39796A (cg-RX-API-DMAC7.html)
WO (1) WO2022254362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250114A1 (es) 2021-06-03 2025-01-16 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
TW202604526A (zh) * 2024-04-29 2026-02-01 美商必治妥美雅史谷比公司 化合物及其治療血色素病變之用途
CN118598797A (zh) * 2024-05-17 2024-09-06 诚达药业股份有限公司 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法
WO2026002044A1 (zh) * 2024-06-25 2026-01-02 标新生物医药科技(上海)有限公司 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543009A (ja) * 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ, インコーポレイテッド 3−ジュウテロ−ポマリドマイド
JP2020504089A (ja) * 2016-12-01 2020-02-06 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
WO2020117759A1 (en) * 2018-12-03 2020-06-11 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
EP3814380A4 (en) 2018-06-29 2022-06-15 Dana Farber Cancer Institute, Inc. BISPECIFIC DEGRADATION PRODUCTS
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
JP7874541B2 (ja) 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
MX2022004526A (es) * 2019-10-17 2022-07-21 Arvinas Operations Inc Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543009A (ja) * 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ, インコーポレイテッド 3−ジュウテロ−ポマリドマイド
JP2020504089A (ja) * 2016-12-01 2020-02-06 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
WO2020117759A1 (en) * 2018-12-03 2020-06-11 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use

Also Published As

Publication number Publication date
WO2022254362A1 (en) 2022-12-08
US20250026736A1 (en) 2025-01-23
CN117062811A (zh) 2023-11-14
TW202306570A (zh) 2023-02-16
AR126052A1 (es) 2023-09-06
BR112023024905A2 (pt) 2024-02-20
ECSP24000004A (es) 2024-02-29
KR20240013812A (ko) 2024-01-30
PY2243958A (es) 2023-01-20
EP4347580A1 (en) 2024-04-10
MX2023014327A (es) 2023-12-13
CL2023003561A1 (es) 2024-06-28
AU2022284366A1 (en) 2023-10-26
UY39796A (es) 2023-07-31
US20230019617A1 (en) 2023-01-19
PE20240657A1 (es) 2024-04-04
CR20230614A (es) 2024-02-01
CO2024000013A2 (es) 2024-01-25
JOP20230308A1 (ar) 2023-11-29
US12103919B2 (en) 2024-10-01
IL308094A (en) 2023-12-01
CA3215410A1 (en) 2022-12-08
DOP2023000261A (es) 2023-12-29

Similar Documents

Publication Publication Date Title
JP7682181B2 (ja) 3-(5-メトキシ-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
US12103919B2 (en) 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7659648B2 (ja) ピラゾロピリジン誘導体及びその使用
US20250276964A1 (en) Benzisoxazole Derivatives and Uses thereof
CN116802182A (zh) 吡唑并吡啶衍生物及其用途
BR122025004894B1 (pt) Uso de derivados de pirazolopiridina, e kit
BR112023018542B1 (pt) Derivados de pirazolopiridina, e composição e combinação farmacêuticas
EA051403B1 (ru) Производные пиразолопиридина и пути их применения
BR122025004894A2 (pt) Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804